Success Rate of Including Medicines to The Reimbursement System In Slovakia.

The analysis can help to understand the most important criteria in local price and reimbursement decision making process. The success rate for inclusion of new drugs is relatively high in Slovakia, but the majority of drugs included to the Reimbursement List do not require higher public expenditures. The most frequent reasons for non-inclusion of a drug to the Reimbursement List were different shortcomings in the pharmacoeconomic analysis. Apart of quantitative analysis there is the need for the evaluation of the quality of submissions and their compliance with the Slovak law and methodology guidelines. Reasons for rejections of submissions In the case of all unsuccessful submissions, in 59% the reason for non-inclusion was the pharmacoeconomic analysis and the most common shortcomings concerned the selection of analysis (14%), selection of comparator (12%) and incorrect calculation of output parameters (12%). Other most frequent reasons were low efficacy, conditional EMA registration, formal shortcomings, and incorrect reference price. In the case of new drugs, which were not included to the reimbursement list, in 64% of cases the reason for non-inclusion was the pharmacoeconomic analysis (Figure 3). METHODS